TY - JOUR
T1 - Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer
AU - Guldner, Laurence
AU - Haddy, Nadia
AU - Pein, François
AU - Diallo, Ibrahima
AU - Shamsaldin, Akthar
AU - Dahan, Michel
AU - Lebidois, Jérome
AU - Merlet, Pascal
AU - Villain, Elisabeth
AU - Sidi, Daniel
AU - Sakiroglu, Olivia
AU - Hartmann, Olivier
AU - Leftakopoulos, Dimitri
AU - de Vathaire, Florent
PY - 2006/10/1
Y1 - 2006/10/1
N2 - Purpose: To determine the cardiac status in children 15 years (yrs) or more after a solid tumour treatment. Patients and Methods: Of the 447 patients, 229 were fully studied and 218 were not. The following cardiac evaluation was proposed to all the 447 consecutive patients: (1) cardiac Doppler US by one of two expert cardiologists; (2) cardiac rhythm and conduction abnormalities including 24-h holter ECG; (3) 131I-mIBG myocardial scintigraphy; (4) serum brain natriuretic peptide levels at rest; (5) an exercise test with VO 2max measurement. The radiation dose delivered to 7 points in the heart was estimated for all patients who had received radiotherapy. Results: Cardiac disorder was diagnosed in 89 evaluated patients (39%) including 24 heart failures and 65 other asymptomatic cardiac diseases. When adjusting on potential confounders, cardiac disorder and cardiac failure risks were respectively linear (ERR at 1 Gy: 26%) and linear-quadratic (ERR at 1 Gy: 19%) functions of the average radiation dose received to the heart. No interaction between cumulative dose of adriamycin and average radiation dose was evidenced for cardiac disorders, but the ERR/Gy of cardiac failure was higher for patients receiving less than 350 mg/m 2 of Adriamycin. Conclusion: Long term heart pathologies are probably one of the major iatrogenic risks encored by patients who survived a childhood cancer. This study strongly emphasizes the need to limit the heart irradiation during radiotherapy, particularly, for patients who also received or were susceptible to later received adriamycin.
AB - Purpose: To determine the cardiac status in children 15 years (yrs) or more after a solid tumour treatment. Patients and Methods: Of the 447 patients, 229 were fully studied and 218 were not. The following cardiac evaluation was proposed to all the 447 consecutive patients: (1) cardiac Doppler US by one of two expert cardiologists; (2) cardiac rhythm and conduction abnormalities including 24-h holter ECG; (3) 131I-mIBG myocardial scintigraphy; (4) serum brain natriuretic peptide levels at rest; (5) an exercise test with VO 2max measurement. The radiation dose delivered to 7 points in the heart was estimated for all patients who had received radiotherapy. Results: Cardiac disorder was diagnosed in 89 evaluated patients (39%) including 24 heart failures and 65 other asymptomatic cardiac diseases. When adjusting on potential confounders, cardiac disorder and cardiac failure risks were respectively linear (ERR at 1 Gy: 26%) and linear-quadratic (ERR at 1 Gy: 19%) functions of the average radiation dose received to the heart. No interaction between cumulative dose of adriamycin and average radiation dose was evidenced for cardiac disorders, but the ERR/Gy of cardiac failure was higher for patients receiving less than 350 mg/m 2 of Adriamycin. Conclusion: Long term heart pathologies are probably one of the major iatrogenic risks encored by patients who survived a childhood cancer. This study strongly emphasizes the need to limit the heart irradiation during radiotherapy, particularly, for patients who also received or were susceptible to later received adriamycin.
KW - Adriamycin
KW - Cardiac abnormalities
KW - Childhood cancer
KW - Radiation
UR - http://www.scopus.com/inward/record.url?scp=33749639503&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2006.08.020
DO - 10.1016/j.radonc.2006.08.020
M3 - Article
C2 - 16989913
AN - SCOPUS:33749639503
SN - 0167-8140
VL - 81
SP - 47
EP - 56
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 1
ER -